Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
32 participants
INTERVENTIONAL
2022-12-19
2025-09-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Incorporating Healthy Living Strategies to Aid in Recovery After Acute Pulmonary Embolism
NCT06784492
PUlmonary REhabilitation in Patients Suffering From Post-PE Syndrome
NCT04615130
Does a Home-based Exercise Programme Affect Physical Capacity and Quality of Life in Patients With Pulmonary Embolism?
NCT02684721
Short-term Clinical Deterioration After Acute Pulmonary Embolism
NCT03915925
Effects of Information and Breathing Technique - for Patients With Respiratory Pain in Acute Pulmonary Embolism.
NCT03375723
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants who receive daily activity message
The intervention group will receive instructions for a daily activity sent through SMS text message or email.
Daily Activity Text
Participants will receive a text each day with instructions about the daily activity they should complete for that day.
Participants who receive control message
The control group will receive daily messages to help with blinding sent through text message or email. The messages will not include activity tasks and will include phrases such as "I hope you have a good day".
Control Text
Participants will receive a text each day with no instructions about daily activity. It will have messages like "have a nice day."
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Daily Activity Text
Participants will receive a text each day with instructions about the daily activity they should complete for that day.
Control Text
Participants will receive a text each day with no instructions about daily activity. It will have messages like "have a nice day."
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute PE with right ventricular enlargement or dysfunction defined by echocardiogram report, CT Angiogram report, or elevated cardiac biomarker (NT-pro BNP or troponin).
* Baseline testing started within 7 days of hospital discharge.
Exclusion Criteria
* Cardiac Effort \>2.5 beats/m during 6MWT. This is for safety.
* Cardiac Effort \<1.2 beats/m during 6MWT. They are unlikely to benefit.
* Resting tachycardia \>120 beats/m during screening or at hospital discharge.
* Suspicion for Chronic Thromboembolic Pulmonary Hypertension.
* Systolic blood pressure \>180 mmHg during screening or at hospital discharge.
* Inability to walk.
* Estimated prognosis \<12 months at the time of discharge due to underlying co-morbidities.
* Advanced neurologic disease.
* Lack of access to email or text messaging.
* Inability to follow daily instructions.
* Participation in a structured exercise routine at least three days per week in the prior four weeks.
* Principal Investigator discretion
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
American College of Chest Physicians
OTHER
University of Rochester
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniel Lachant
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Lachant, DO
Role: PRINCIPAL_INVESTIGATOR
University of Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Rochester Medical Center
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00007680
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.